Tomuzotuximab is a glycoengineered, humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Developed as an optimized derivative of cetuximab through glycan modification, the compound aims to enhance the clearance of EGFR-overexpressing tumor cells by boosting antibody-dependent cellular cytotoxicity (ADCC). It serves as an essential tool for investigating the synergy between receptor tyrosine kinase signaling blockade and immune effector enhancement.